Analysis of the targeting mechanism of ernatumumab

Eranatamab (Elranatamab) is a bispecific T cell-engaging antibody that belongs to a new generation of targeted immunotherapy drugs. It is designed for the treatment of relapsed or refractory multiple myeloma (RRMM). Its unique mechanism of action is based on the ability to recognize two cell surface antigens at the same time: one end targets the B cell maturation antigen (BCMA) on the surface of myeloma cells, and the other end targets the CD3 receptor on the surface of T cells, thus "drawing" T cells directly to the tumor cells and triggering a T cell-mediated tumor cell lysis reaction.

BCMA is a signature antigen specifically expressed by multiple myeloma cells and is almost not expressed in normal cells. This feature makes enantuzumab highly selective and minimizes damage to normal tissues. CD3-mediated activation of T cells can quickly activate the immune killing effect without relying on tumor antigen presentation or MHC pathways, allowing it to show efficacy even in patients who are resistant to traditional therapies.

The advantage of Eractuzumab is that it is constructed as a fully human antibody with low immunogenicity, which helps to improve the safety and tolerability of long-term administration. Its subcutaneous injection form is more convenient to operate than intravenous injection, reduces hospitalization dependence, and improves patient treatment compliance. This mechanism has shown significant tumor burden clearance effects in multiple myeloma patients in multiple clinical studies, making it one of the most promising drugs in the field of BCMA targeting.

In general, enatumumab simultaneously activates immune cells and accurately attacks tumor cells through a dual-antibody structure, breaking through the traditional treatment model and providing a powerful immune weapon for the later-line treatment of multiple myeloma.

Reference materials:https://www.drugs.com/mtm/elranatamab.html